Italy In Vivo Cro Market Size & Outlook, 2023-2030
Italy in vivo cro market, 2018-2030 (US$M)
Related Markets
Italy in vivo cro market highlights
- The Italy in vivo cro market generated a revenue of USD 174.0 million in 2023 and is expected to reach USD 309.3 million by 2030.
- The Italy market is expected to grow at a CAGR of 8.6% from 2024 to 2030.
- In terms of segment, small molecule was the largest revenue generating modality type in 2023.
- Large Molecule is the most lucrative modality type segment registering the fastest growth during the forecast period.
In vivo cro market data book summary
| Market revenue in 2023 | USD 174.0 million |
| Market revenue in 2030 | USD 309.3 million |
| Growth rate | 8.6% (CAGR from 2023 to 2030) |
| Largest segment | Small molecule |
| Fastest growing segment | Large Molecule |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Small Molecule, Large Molecule |
| Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Other key industry trends
- In terms of revenue, Italy accounted for 3.8% of the global in vivo cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany in vivo cro market is projected to lead the regional market in terms of revenue in 2030.
- Spain is the fastest growing regional market in Europe and is projected to reach USD 328.5 million by 2030.
Small molecule was the largest segment with a revenue share of 63.62% in 2023. Horizon Databook has segmented the Italy in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
Several CROs offer a variety of services in Italy, especially in the field of preclinical and clinical contract research. Approximately 800 companies are operating in Italy’s pharmaceutical and biotech industry, accounting for nearly 7% of total global R&D investments.
This can be attributed to the growth of the in vivo CRO market in the country. Furthermore, the constant allocation of funds by the Italian government is supporting the R&D activities in the country. This support helps in vivo CROs in Italy to invest in infrastructure and technology, boosting the market. However, CROs encounter regulatory and bureaucratic obstacles, which may act as market barriers in Italy.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
In Vivo CRO Market Scope
In Vivo CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Italy in vivo cro market size, by modality type, 2018-2030 (US$M)
Italy In Vivo CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
